subscribeSubscribe
price-trendAsk Us
Vector Pharma FZCO Announce Agreement with Ascendis for Skytrofa

Vector Pharma FZCO Announce Agreement with Ascendis for Skytrofa
GLOBENEWSWIRE
08 Jan 2024
Share Share
TransCon Achieved Superior Outcomes Compared to Placebo in Ph 3 foresiGHt Trial

TransCon Achieved Superior Outcomes Compared to Placebo in Ph 3 foresiGHt Trial
GLOBENEWSWIRE
19 Dec 2023
Share Share
Ascendis Pharma Launches SKYTROFA in Germany

Ascendis Pharma Launches SKYTROFA in Germany
GLOBENEWSWIRE
15 Sep 2023
Share Share
Ascendis` Biologic Skytrofa (Lonapegsomatropin) Receives Approval in the U.S.

Ascendis` Biologic Skytrofa (Lonapegsomatropin) Receives Approval in the U.S.
FDA
20 Oct 2022
Share Share
VISEN Pharma`s Top-line Results of PIII Trial of Once-Weekly Lonapegsomatropin

VISEN Pharma`s Top-line Results of PIII Trial of Once-Weekly Lonapegsomatropin
PRNEWSWIRE
23 May 2022
Share Share
Ascendis Pharma to Present New Endocrinology Results at 4 Medical Meetings

Ascendis Pharma to Present New Endocrinology Results at 4 Medical Meetings
GLOBENEWSWIRE
01 May 2022
Share Share
Ascendis Pharma`s Lonapegsomatropin Receives Approval in Europe

Ascendis Pharma`s Lonapegsomatropin Receives Approval in Europe
EMA
11 Jan 2022
Share Share